Confession season is over, so it would be very poor form to downgrade now. Particularly after such strong reaffirmation so recently. It's a competitive industry, but RXP's current value and improving margin is a standout.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025